GlassScriptPhysician profile
Sarah Sumida
NPI 1891510103
$3,050.42
in general payments reported to CMS, 2019-2025
14 companies · $3,050 in 2025
The $3,050 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.53 |
| Education | $303.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $594.44 | 2025 | Zoryve |
| Abbvie INC. | $459.76 | 2025 | |
| Sun Pharmaceutical Industries INC. | $346.57 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $286.62 | 2025 | Dupixent |
| Ucb, INC. | $257.18 | 2025 | Bimzelx |
| Lilly USA, LLC | $246.28 | 2025 | Ebglyss, Taltz |
| Organon LLC | $196.32 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $164.73 | 2025 | Sotyktu |
| Galderma Laboratories, L.P. | $152.87 | 2025 | Nemluvio |
| Genzyme Corporation | $125.34 | 2025 | |
| Leo Pharma INC. | $90.87 | 2025 | Adbry, Anzupgo |
| Amgen INC. | $56.14 | 2025 | Otezla |
| Pfizer INC. | $49.53 | 2025 | |
| Incyte Corporation | $23.77 | 2025 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Sumida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.